AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8509823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial mannitol infusion (50 ml of 20% mannitol at 50 ml/min) prior to ACNU and CDDP (100 mg/body at 20 mg/min)
Number of subjects: 98
Study 8509823 — intervention group
Group type: COMPARATOR
Intervention: ACNU and CDDP (100 mg/body at 20 mg/min) without mannitol infusion
Number of subjects: 98
Study 2862516 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and acyclovir combination therapy
Number of subjects: 0
Study 2862516 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 0
Study 2862516 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir alone
Number of subjects: 0
Study 31298466 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation during VLCKD
Number of subjects: 33
Study 31298466 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo during VLCKD and synbiotics during LCD
Number of subjects: 33
Study 31298466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 33
Study 29362795 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed therapy (10 sessions over 2 weeks)
Number of subjects: 370
Study 29362795 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact control (MCC; telephone calls from therapists, once weekly for 4 weeks)
Number of subjects: 370
Study 29362795 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced therapy (10 sessions over 8 weeks)
Number of subjects: 370
Study 29362795 — intervention group
Group type: EXPERIMENTAL
Intervention: Present-centered therapy (PCT; 10 sessions over 8 weeks)
Number of subjects: 370
Study 26815734 — intervention group
Group type: EXPERIMENTAL
Intervention: Insole with metatarsal and medial arch supports
Number of subjects: 80
Study 26815734 — intervention group
Group type: COMPARATOR
Intervention: Flat insole
Number of subjects: 80
Study 25594166 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (0.3 g/d)
Number of subjects: 97
Study 25594166 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (1.3 g/d)
Number of subjects: 97
Study 25594166 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+α-lipoic acid (1.3 g/d + 0.3 g/d)
Number of subjects: 97
Study 25594166 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 97
Study 22406434 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrate (0.15 mmol/kg or 12.7 mg/kg) in 150 ml water
Number of subjects: 0
Study 22406434 — intervention group
Group type: COMPARATOR
Intervention: Water alone (control)
Number of subjects: 0
Study 20363308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron Rapidfilm
Number of subjects: 24
Study 20363308 — intervention group
Group type: COMPARATOR
Intervention: Zofran Zydis Lingual ODT
Number of subjects: 24
Study 18592783 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly nedaplatin (30 mg/mm2/time, once a week, total 150 mg/mm2/5 weeks) combined with radiation therapy (50 Gy-52 Gy/25-27 fractions with central shielding after 30-32 Gy and high-dose rate intracavitary irradiation 24-30 Gy/4-6 fractions to point A)
Number of subjects: 45
Study 18592783 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly nedaplatin combined with radiation therapy
Number of subjects: 45
Study 15977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl (BF)
Number of subjects: 60
Study 15977094 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine-morphine (BM)
Number of subjects: 60
Study 12646507 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber (13.5 g/day)
Number of subjects: 68
Study 12646507 — intervention group
Group type: COMPARATOR
Intervention: Low fiber (2.0 g/day)
Number of subjects: 68
Study 10332461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincterotomy
Number of subjects: 57
Study 10332461 — intervention group
Group type: COMPARATOR
Intervention: Sphincteric stent placement
Number of subjects: 57
Study 7788131 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 4
Study 7788131 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 4
Study 3391002 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 120 mg every 8 hours for 7 days
Number of subjects: 12
Study 3391002 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem, 90 mg every 8 hours for 7 days
Number of subjects: 12
Study 3391002 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg every 8 hours for 7 days
Number of subjects: 12
Study 3391002 — intervention group
Group type: COMPARATOR
Intervention: Control (theophylline alone, 5 mg/kg)
Number of subjects: 12
Study 1054222 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminar air flow room reverse isolation with oral nonabsorbable antibiotics (LAF plus A)
Number of subjects: 64
Study 1054222 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine hospital ward care with antibiotics (W plus A)
Number of subjects: 64
Study 1054222 — intervention group
Group type: COMPARATOR
Intervention: Ward care alone (W)
Number of subjects: 64
Study 31752905 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 26
Study 31752905 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 26
Study 28652968 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic CR neuromodulation
Number of subjects: 18
Study 28652968 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy CR-like stimulation
Number of subjects: 18
Study 28652968 — intervention group
Group type: COMPARATOR
Intervention: Low frequency range (LFR) stimulation
Number of subjects: 18
Study 26902007 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative infiltration of local anesthesia at the wound site
Number of subjects: 58
Study 26902007 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 58
Study 23242843 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI at 5 μg/mL for 2 min followed by 3 μg/mL
Number of subjects: 50
Study 23242843 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 5% at inhaled concentration
Number of subjects: 50
Study 21526413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-initiated medication use review
Number of subjects: 400
Study 18073485 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental removal at 20 min
Number of subjects: 1607
Study 18073485 — intervention group
Group type: COMPARATOR
Intervention: Placental removal at 30 min
Number of subjects: 1607
Study 18073485 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age > or =35 years
Number of subjects: 1607
Study 18073485 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of second stage of labor >2 h
Number of subjects: 1607
Study 18073485 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorioamnionitis
Number of subjects: 1607
Study 18073485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 1607
Study 18073485 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdistended uterus
Number of subjects: 1607
Study 18073485 — intervention group
Group type: EXPERIMENTAL
Intervention: Third stage of labor >10 min
Number of subjects: 1607
Study 21198365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-phone conversation or text-message task during study
Number of subjects: 0
Study 21198365 — intervention group
Group type: COMPARATOR
Intervention: No distractions during study
Number of subjects: 0
Study 21198365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-phone or text-message distractions present
Number of subjects: 0
Study 21198365 — intervention group
Group type: COMPARATOR
Intervention: Cell-phone or text-message distractions absent
Number of subjects: 0
Study 21198365 — intervention group
Group type: EXPERIMENTAL
Intervention: All distraction conditions
Number of subjects: 0
Study 17877128 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol therapy (ET)
Number of subjects: 120
Study 17877128 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women (group M)
Number of subjects: 120
Study 17877128 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women (group K)
Number of subjects: 120
Study 17877128 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA-S concentration in group K
Number of subjects: 120
Study 17877128 — intervention group
Group type: COMPARATOR
Intervention: DHEA-S concentration in group M
Number of subjects: 120
Study 11809183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 122
Study 11809183 — intervention group
Group type: COMPARATOR
Intervention: High-dose methylprednisolone
Number of subjects: 122
Study 11809183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin with oral prednisone
Number of subjects: 122
Study 11809183 — intervention group
Group type: COMPARATOR
Intervention: High-dose methylprednisolone with oral prednisone
Number of subjects: 122
Study 9466467 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory agents
Number of subjects: 0
Study 9466467 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical trials using models of sepsis and shock
Number of subjects: 0
Study 9466467 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials of agents based on clinically flawed models
Number of subjects: 0
Study 8056888 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% benzoyl peroxide gel applied once a day for 7 days before surgery
Number of subjects: 673
Study 8056888 — intervention group
Group type: COMPARATOR
Intervention: No antibacterial prophylaxis
Number of subjects: 673
Study 2972270 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride therapy
Number of subjects: 10
Study 15830485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin (1 g intravenous dose) over 120, 30, and 3 min
Number of subjects: 12
Study 15830485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (1 g intravenous dose) over 120, 30, and 3 min
Number of subjects: 12
Study 15830485 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (1 g intravenous infusion) prior to cephalothin
Number of subjects: 12
Study 15830485 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (1 g intravenous infusion) prior to cefoxitin
Number of subjects: 12
Study 15830485 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 12
Study 15830485 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 12
Study 27575015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Treadmill Training (HITT)
Number of subjects: 16
Study 27575015 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Treadmill Training (LITT)
Number of subjects: 16
Study 27249461 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional 1064-nm QSNY
Number of subjects: 13
Study 27249461 — intervention group
Group type: COMPARATOR
Intervention: Conventional 1064-nm QSNY
Number of subjects: 13
Study 27249461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Fractional and Conventional 1064-nm QSNY)
Number of subjects: 13
Study 24597283 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal support with progesterone
Number of subjects: 110
Study 24597283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no luteal support)
Number of subjects: 110
Study 21885068 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen sponge
Number of subjects: 720
Study 21885068 — intervention group
Group type: COMPARATOR
Intervention: Control (collagen sponge)
Number of subjects: 720
Study 20146965 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet (counselled group)
Number of subjects: 211
Study 20146965 — intervention group
Group type: COMPARATOR
Intervention: Non-counselled group (control)
Number of subjects: 211
Study 18335515 — intervention group
Group type: EXPERIMENTAL
Intervention: MYO-029 at 1 mg/kg
Number of subjects: 116
Study 18335515 — intervention group
Group type: EXPERIMENTAL
Intervention: MYO-029 at 3 mg/kg
Number of subjects: 116
Study 18335515 — intervention group
Group type: EXPERIMENTAL
Intervention: MYO-029 at 10 mg/kg
Number of subjects: 116
Study 18335515 — intervention group
Group type: EXPERIMENTAL
Intervention: MYO-029 at 30 mg/kg
Number of subjects: 116
Study 18335515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 18335515 — intervention group
Group type: EXPERIMENTAL
Intervention: MYO-029 (all doses)
Number of subjects: 116
Study 15709851 — intervention group
Group type: EXPERIMENTAL
Intervention: Divorce mediation
Number of subjects: 0
Study 15709851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacceptance (mothers)
Number of subjects: 0
Study 15709851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacceptance (fathers)
Number of subjects: 0
Study 11796346 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine encapsulated enteric bead formulation (400 mg) with indinavir (800 mg)
Number of subjects: 63
Study 11796346 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine encapsulated enteric bead formulation (400 mg) with ketoconazole (200 mg)
Number of subjects: 63
Study 11796346 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine encapsulated enteric bead formulation (400 mg) with ciprofloxacin (750 mg)
Number of subjects: 63
Study 10404825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin
Number of subjects: 15
Study 10404825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin plus CRH
Number of subjects: 15
Study 10404825 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH
Number of subjects: 15
Study 10404825 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 15
Study 7748217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 3 gm/day
Number of subjects: 351
Study 7748217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 7748217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ)
Number of subjects: 351
Study 2109121 — intervention group
Group type: EXPERIMENTAL
Intervention: Hausmann Lipid 20%
Number of subjects: 13
Study 2109121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipovenös 20%
Number of subjects: 13
Study 2109121 — intervention group
Group type: COMPARATOR
Intervention: Intralipid 20%
Number of subjects: 13
Study 379052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation
Number of subjects: 18
Study 379052 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation
Number of subjects: 18
Study 31825499 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS intervention group (3242 patients)
Number of subjects: 6480
Study 31825499 — intervention group
Group type: COMPARATOR
Intervention: Control group (3238 patients)
Number of subjects: 6480
Study 31825499 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS intervention group
Number of subjects: 6480
Study 28956706 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity Intervention (EPAI)
Number of subjects: 211
Study 28956706 — intervention group
Group type: COMPARATOR
Intervention: Caregiver Skill Building Intervention (CSBI)
Number of subjects: 211
Study 25853611 — intervention group
Group type: EXPERIMENTAL
Intervention: CROS hearing aid
Number of subjects: 8
Study 25853611 — intervention group
Group type: EXPERIMENTAL
Intervention: BAHD
Number of subjects: 8
Study 23278176 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C (1400 mg) and E (800 mg) supplementation
Number of subjects: 83
Study 23278176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 20492527 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical OLEOZON(®), applied two times per day for 3 months
Number of subjects: 400
Study 20492527 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole cream 2%, applied two times per day for 3 months
Number of subjects: 400
Study 20492527 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical OLEOZON(®)
Number of subjects: 400
Study 20492527 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole cream 2%
Number of subjects: 400
Study 19652547 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the vaccine trial
Number of subjects: 503
Study 19652547 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint decision-making within households
Number of subjects: 503
Study 19652547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of information and negative information
Number of subjects: 503
Study 17275896 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention
Number of subjects: 24
Study 12680737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.0 mg)
Number of subjects: 36
Study 12680737 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1.2 mg)
Number of subjects: 36
Study 12680737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10760556 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ECT with antidepressant drugs (Group-1)
Number of subjects: 30
Study 10760556 — intervention group
Group type: COMPARATOR
Intervention: Unilateral ECT with drug placebo (Group-2)
Number of subjects: 30
Study 8822997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated-fat, low-cholesterol diet with dietary counseling
Number of subjects: 1062
Study 8822997 — intervention group
Group type: COMPARATOR
Intervention: Control group with unrestricted diet
Number of subjects: 1062
Study 1448485 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoking
Number of subjects: 48
Study 1448485 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged breath holding
Number of subjects: 48
Study 1448485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3881924 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate, low fat diet (65% carbohydrate, 20% fat, 15% protein) for six weeks
Number of subjects: 6
Study 3881924 — intervention group
Group type: COMPARATOR
Intervention: Control diet (45% carbohydrate, 40% fat, 15% protein) for four weeks
Number of subjects: 6
Study 30777070 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate + amodiaquine (AS + AQ)
Number of subjects: 749
Study 30777070 — intervention group
Group type: COMPARATOR
Intervention: artesunate + sulfadoxine‐pyrimethamine (AS + SP)
Number of subjects: 749
Study 30777070 — intervention group
Group type: COMPARATOR
Intervention: artesunate (AS)
Number of subjects: 749
Study 29985669 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min pre-exercise nap (NAP)
Number of subjects: 61
Study 29985669 — intervention group
Group type: COMPARATOR
Intervention: Control group without pre-exercise nap (CON)
Number of subjects: 61
Study 27348250 — intervention group
Group type: COMPARATOR
Intervention: GSK TIV
Number of subjects: 292
Study 27348250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinovac TIV
Number of subjects: 292
Study 27348250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteur TIV
Number of subjects: 292
Study 27348250 — intervention group
Group type: EXPERIMENTAL
Intervention: All TIVs
Number of subjects: 292
Study 27348250 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinovac TIV, Pasteur TIV, GSK TIV
Number of subjects: 292
Study 24670677 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging popular tags (n=61)
Number of subjects: 174
Study 24670677 — intervention group
Group type: COMPARATOR
Intervention: Bias-supporting tag clouds (n=56)
Number of subjects: 174
Study 24670677 — intervention group
Group type: COMPARATOR
Intervention: Balanced tag clouds (n=57)
Number of subjects: 174
Study 24670677 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging explicit expert information (n=93)
Number of subjects: 174
Study 24670677 — intervention group
Group type: COMPARATOR
Intervention: Supporting expert information (n=81)
Number of subjects: 174
Study 22997073 — intervention group
Group type: EXPERIMENTAL
Intervention: OBR + ENF
Number of subjects: 29
Study 22997073 — intervention group
Group type: COMPARATOR
Intervention: OBR
Number of subjects: 29
Study 20576837 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion control, stability, or cushioned shoes based on plantar shape (experimental group)
Number of subjects: 1111
Study 20576837 — intervention group
Group type: COMPARATOR
Intervention: Stability shoe regardless of plantar shape (control group)
Number of subjects: 1111
Study 18034628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured autologous keratinocytes delivered on chemically defined transfer discs (Myskin)
Number of subjects: 16
Study 18034628 — intervention group
Group type: COMPARATOR
Intervention: Cell-free discs (placebo)
Number of subjects: 16
Study 16195293 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach sessions delivered to nurse practitioners (2-6 sessions).
Number of subjects: 1999
Study 12097668 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine infusion at 4.1 mg/(kg. 12 h)
Number of subjects: 10
Study 12097668 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine infusion at 6.6 mg/(kg. 12 h)
Number of subjects: 10
Study 12097668 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine infusion at 8.3 mg/(kg. 12 h)
Number of subjects: 10
Study 12097668 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine infusion (all rates)
Number of subjects: 10
Study 9827735 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute EMLA cream
Number of subjects: 40
Study 9827735 — intervention group
Group type: COMPARATOR
Intervention: 20-minute placebo cream
Number of subjects: 40
Study 8116352 — intervention group
Group type: EXPERIMENTAL
Intervention: Marvelon (30 micrograms ethinyl estradiol)
Number of subjects: 60
Study 8116352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercilon (20 micrograms ethinyl estradiol)
Number of subjects: 60
Study 2571326 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride ophthalmic solution
Number of subjects: 353
Study 2571326 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate ophthalmic solution
Number of subjects: 353
Study 22295 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol premedication (0.3 to 0.5 mg/kg)
Number of subjects: 0
Study 22295 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital and Dolosal-promethazine
Number of subjects: 0
Study 30357066 — intervention group
Group type: EXPERIMENTAL
Intervention: hEAR mobile application with Pioneer HDJ‐2000 headphones
Number of subjects: 30